Mission Statement, Vision, & Core Values (2026) of Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Born in 2001 and rooted in Zhongguancun Life Science Park, Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) has grown into a high-tech biomedical powerhouse with a 40,000‑square‑meter R&D center, diversified manufacturing footprints in Shijiazhuang and Shantou and facilities underway in Qujing and Hohhot, and a public listing on ChiNext since May 2012; guided by a mission to pioneer high‑quality biotech solutions, Bohui allocates roughly 10% of annual revenue to R&D, launched over 15 new products last fiscal year driving a reported 20% year‑over‑year revenue increase while targeting a 90% customer satisfaction score, and its forward‑looking vision commits to a $5 million community health investment in 2024, carbon neutrality by 2030, and strategic expansion through partnerships with at least 10 major pharmaceutical companies to translate innovation into global healthcare impact.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Intro

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) was established in 2001 and has grown into a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. Headquartered in Zhongguancun Life Science Park, Beijing, the company operates a comprehensive R&D center covering approximately 40,000 square meters. In May 2012 Bohui Group was listed on the Shenzhen Stock Exchange ChiNext (Stock Code: 300318). The company's core product lines include microfluidic automated nucleic acid detection systems, immunofluorescence detection products, and mass spectrometry analysis instruments, alongside expanding blood product manufacturing capabilities in multiple provinces.

Mission

• Develop reliable, high‑precision diagnostic and life‑science tools that improve clinical decision‑making and public health outcomes.
• Translate advanced biomedical research into scalable industrialized products and services for hospitals, laboratories, and blood centers.

Vision

• Becoming a leading internationally recognized Chinese innovator in in vitro diagnostics and blood product manufacturing, driven by technology and quality.
• Establish an integrated ecosystem from R&D to industrial production that accelerates translation of national science initiatives into marketable solutions.

Core Values

• Scientific integrity - rigorous validation, compliance with regulatory and quality standards.
• Innovation-driven growth - continuous investment in platform R&D and adoption of microfluidics, automation, and mass spectrometry technologies.
• Customer-centricity - delivering robust products, service support and after-sales to clinical and industrial partners.
• Industrialization and scalability - focus on manufacturing capability expansion (multi-site blood product facilities) and process standardization.
• Talent cultivation - building state-approved R&D platforms and talent bases under national programs.

Strategic positioning emphasizes alignment with national science and industrialization priorities; Bohui Group has undertaken major national scientific‑industrialization projects under the 12th and 13th Five‑Year Plans and the National 863 Program, securing state‑level R&D platforms and talent bases that underpin product pipelines and manufacturing scale‑up. For a detailed financial breakdown and investor‑focused analysis, see: Breaking Down Beijing Bohui Innovation Biotechnology Group Co., Ltd. Financial Health: Key Insights for Investors

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Overview

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) centers its corporate mission on pioneering high-quality biotech solutions that address critical health challenges while maintaining rigorous ethics and customer focus.

• Mission: Pioneer high-quality biotech solutions addressing critical health challenges with innovation, quality, and accessibility.
• R&D commitment: Approximately 10% of annual revenue allocated to research and development activities.
• Product output: Launched over 15 new products in the last fiscal year.
• Customer focus: Annual customer satisfaction surveys with a target score of 90%.
• Governance: Strong adherence to business ethics and corporate governance standards across operations.

Financial and operational indicators demonstrate the mission translating into measurable results and resource allocation.

Strategic priorities and core values are operationalized through focused initiatives and measurable KPIs:

• Innovation: Sustained R&D investment (10% of revenue) and pipeline acceleration - over 15 product launches in the last fiscal year.
• Quality: Regulatory compliance and quality systems aligned to ISO/GMP standards; continuous improvement targets embedded in manufacturing and QA.
• Accessibility: Pricing, distribution, and partnership programs to broaden patient access; customer satisfaction target of 90% measured annually.
• Integrity: Corporate governance frameworks, compliance training, and transparent reporting to uphold ethical standards.
• Sustainability: Environmental and social governance initiatives integrated into operations and supplier management.

Key performance metrics used to align strategic decisions with the mission include R&D intensity, product launch cadence, revenue growth, net margin, and customer satisfaction scores. For a deeper financial analysis, see Breaking Down Beijing Bohui Innovation Biotechnology Group Co., Ltd. Financial Health: Key Insights for Investors

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Mission Statement

• Develop next-generation therapeutics, diagnostics, and biologics that respond to evolving global healthcare needs.
• Prioritize continuous innovation in R&D to shorten development cycles and increase clinical success rates.
• Operate with sustainability and ethical responsibility at the core of business decisions.
• Forge strategic collaborations to expand geographic reach and market access.

• Investment in community health initiatives: $5,000,000 allocated for 2024 programs focused on preventive care and capacity building.
• Environmental commitment: achieve carbon-neutral operations by 2030.
• Geographic expansion targets: expand influence across North America, Europe, and Asia with prioritized regulatory and commercial pathways.
• Partnership ambition: target collaborations with at least 10 major pharmaceutical companies to accelerate product development and market penetration.

• R&D acceleration: prioritize translational programs and platform technologies to increase candidate throughput and clinical readiness.
• Collaborative model: combine in-house capabilities with external partners to de-risk development and scale manufacturing.
• Sustainability governance: implement measurable KPIs for emissions, energy use, and supply-chain impacts to track progress toward 2030 carbon neutrality.
• Community impact metrics: track beneficiaries, program reach, and health outcomes from the $5M 2024 investment to ensure measurable public-health returns.

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ) - Vision Statement

• Integrity: adherence to laws, ethical standards, and transparent governance that form the foundation of corporate life.
• Cooperation: cross-functional teamwork, strategic partnerships, and open collaboration to achieve superior outcomes.
• Innovation: continuous R&D investment, technology adoption, and product pipeline expansion to create differentiated solutions.
• Excellence: rigorous quality systems, performance benchmarks, and continuous improvement across operations.

• Policy integration - codes of conduct, compliance training, and supplier standards that embed integrity and responsibility.
• Organizational design - matrix teams and joint ventures that institutionalize cooperation and knowledge sharing.
• R&D focus - dedicated funding streams and innovation incentives that prioritize breakthrough development.
• Quality management - GxP, ISO-aligned systems, and KPIs that ensure excellence in products and services.

• Integrity ensures sustainable access to regulated markets and investor trust, reducing compliance risk and enhancing long-term valuation.
• Cooperation accelerates time-to-market through partnerships with hospitals, research institutes, and industry peers.
• Innovation expands the product pipeline and service offerings, supported by measured R&D spend and talent retention.
• Excellence raises operational efficiency, product quality, and customer satisfaction, driving repeat business and margin improvement.